佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-11 | 6083.28万 | -142.44万 | -2.29% | | 2025-12-10 | 6225.72万 | -21.42万 | -0.34% | | 2025-12-09 | 6247.14万 | 1.02万 | 0.02% | | 2025-12-08 | 6246.12万 | -51.36万 | -0.82% | | 2025-12-05 | 6297.4 ...

日前，华证指数公布了新一期（2025年10月31日）的ESG评级结果，佰泽医疗（02609.HK）获得CCC 评级（华证指数评级为C起至AAA九档，C为最低档，AAA为其最高一级评级/AA为其第二档）。本期 ESG评级在16家医疗保健提供商与服务行业港股上市公司中排名第15。 【ESG小知识】什么是ESG？ESG是Environmental, Social and Governance的缩写，即环境、社会和治 理。ESG 指标分别从环境、社会以及公司治理角度，来衡量企业发展的可持续性。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从细项得分来看，佰泽医疗E项得分54.89，评级为C，行业内排名15/16（E项目评分维度包括气候变 化、资源利用、环境污染、环境管理）；S项得分70.42，评级为B，行业内排名15/16（S项目评分维度 包括人力资本、供应商、社会贡献、数据安全与隐私）；G项得分80.2，评级为BBB，行业内排名7/16 （G项目评分维度包括股东权益、治理结构、信披质量、治理风险、外部处分、商业道德）。 上海华证指数信 ...

Core Insights - As of December 10, 30 stocks reached their 52-week highs, with Design Metropolis (01545), Platinum Holdings (00459), and China Boton (03318) leading the increase rates at 40.82%, 35.48%, and 30.23% respectively [1][2] 52-Week Highs - Design Metropolis (01545) closed at 0.124, with a peak of 0.138, achieving a high rate of 40.82% [1] - Platinum Holdings (00459) closed at 0.121, with a peak of 0.126, achieving a high rate of 35.48% [1] - China Boton (03318) closed at 2.090, with a peak of 2.800, achieving a high rate of 30.23% [1] - Other notable stocks include: - China New Holdings (08125) at 25.00% [1] - Qiaoyang International Holdings (08070) at 14.46% [1] 52-Week Lows - The stock with the largest decline was Jingye Mingbang Group (02231), which fell to 0.099, a decrease of 26.40% [2] - Other significant declines included: - Zhonggang Petroleum (00632) at -16.40% [2] - Guofu Hydrogen Energy (02582) at -13.31% [2] - Additional stocks with notable declines: - Haotian International Construction Investment (01341) at -11.11% [2] - Jiaming Group Holdings (01271) at -10.00% [2]

证券之星消息，12月9日南向资金增持1.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有1天，累计净减持38.28万股。近20个交易日中，获南向资金减持的有10天，累计净减持200.94万 股。截至目前，南向资金持有佰泽医疗（02609.HK）6247.14万股，占公司已发行普通股的4.73%。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

（原标题：融合聚力 精准康复！2025肿瘤康复论坛在天津举办） 共襄学术盛举，擘画肿瘤康复蓝图。12月5日，由天津市抗癌协会癌症康复工作委员会主办、佰泽医疗 集团协办的"融合聚力 精准康复——2025肿瘤康复论坛"在天津举办。本次论坛汇聚了肿瘤治疗、康 复、心理及中医等多领域权威专家，聚焦肿瘤康复前沿理念与实践路径，旨在推动肿瘤全周期管理模式 下康复医学的融合发展，提升患者生存质量。 《健康中国行动（2019—2030年）》指出，癌症严重影响人民健康，要重视康复治疗。《健康中国行动 —癌症防治行动实施方案（2023—2030年）》进一步明确：加强诊疗规范化管理，做好患者康复指导、 疼痛管理、长期护理和营养、心理支持。随着健康中国战略的深入推进和医学进步，我国肿瘤诊疗水平 显著提升，患者生存期持续延长。如何助力患者在延长生存时间的同时，全面提升其生活质量，促进其 身心的完整康复，已成为大家共同面临的时代课题。 基于此，佰泽医疗集团携旗下天津石氏医院协办此次大会。佰泽医疗集团（02609.HK）致力于打造中 国领先的肿瘤全周期医疗集团，经营6家自有民营营利性医院，管理及运营2家民营非营利性医院。作为 佰泽医疗集团 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | 第 2 頁 共 10 ...

Group 1 - The core point of the article is that southbound funds have increased their holdings in Baize Medical (02609.HK) by 132,600 shares on November 21, 2025, with a total net increase of 1,084,000 shares over the past 20 trading days [1][2] - As of now, southbound funds hold a total of 63,736,800 shares of Baize Medical, accounting for 4.82% of the company's total issued ordinary shares [1][2] - The company operates primarily in the oncology medical services sector, providing a full cycle of medical services including screening, diagnosis, treatment, and rehabilitation [2] Group 2 - The trading data shows fluctuations in shareholding over the past few days, with a net increase of 10,920 shares over the last five trading days [2] - The company is involved in various aspects of oncology care, including cancer diagnosis, treatment, rehabilitation, and palliative care, as well as early cancer screening and health management services [2]

Core Viewpoint - Southbound funds have increased their holdings in Baize Medical (02609.HK) by 103,200 shares on November 20, 2025, indicating a potential positive sentiment towards the company in the market [1]. Summary by Sections Southbound Fund Activity - In the last five trading days, southbound funds have increased their holdings for three days, with a total net increase of 58,200 shares [1]. - Over the past 20 trading days, there have been 12 days of net reductions, totaling 1,262,400 shares [1]. - As of now, southbound funds hold 63,604,200 shares of Baize Medical, accounting for 4.81% of the company's total issued ordinary shares [1]. Shareholding Changes - On November 20, 2025, the total number of shares held was 63,604,200, with a change of 103,200 shares, reflecting a 0.16% increase [2]. - On November 19, 2025, the total was 63,501,000 shares, with a decrease of 150,600 shares, showing a -0.24% change [2]. - On November 18, 2025, the total was 63,651,600 shares, with an increase of 176,400 shares, indicating a 0.28% rise [2]. - On November 17, 2025, the total was 63,475,200 shares, with a decrease of 152,400 shares, reflecting a -0.24% change [2]. - On November 14, 2025, the total was 63,627,600 shares, with an increase of 81,600 shares, showing a 0.13% rise [2]. Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2]. - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2]. - Its business encompasses hospital operations, management services, supply of pharmaceuticals, medical devices, consumables, and other related services [2]. - The company also conducts early cancer screening, tumor vaccination, and health management services for potential healthy populations, primarily operating in the Chinese market [2].

Summary of Global Metals & Mining Conference Call Industry Overview - The mining industry is facing challenges in organic production growth due to slow permitting processes, geopolitical instability, and shareholder expectations for dividends and buybacks. This has made inorganic growth through mergers and acquisitions (M&A) more attractive [1][2][3]. Key Trends in M&A Activity - Historically, high sector EBITDA margins correlate with increased M&A activity. Current margins are slightly above long-term averages, suggesting a potential increase in M&A deals if commodity prices remain stable [2][14]. - Recent M&A activity has been robust, with notable deals including RIO & Arcadium Lithium, BHP/Lundin & Filo, and potential transactions involving Anglo American and Teck [2][6]. Credit Environment and M&A - M&A activity tends to thrive in periods of low yield spreads and when banks loosen lending standards. The current credit backdrop, characterized by lower dollar interest rates and relaxed lending policies, supports the expectation of continued M&A activity [3][17]. M&A Deal Volume and Value - In 2023 and 2024, gold dominated M&A activity with nearly half of the deal volume at $48 billion, followed by iron ore at $20 billion. Copper deals totaled $11.7 billion, indicating a significant interest in this commodity [4][33]. - Between 2016 and 2024, copper pureplays invested $96 billion in organic capex, while copper M&A totaled $74 billion. This trend raises concerns about potential future copper deficits by 2029 [5][6]. Future M&A Opportunities - Potential future M&A opportunities include the anticipated Anglo-American and Teck transaction, as well as possible mergers between Newmont and Barrick. The scarcity of medium-sized pure-play copper companies like Ivanhoe and First Quantum may drive further acquisitions [6][9]. Investment Ratings and Price Targets - Outperform ratings are given to companies such as ABX, FCX, and RIO, with RIO's price target increased from GBP 50.00 to GBP 52.00 based on Q3 production results [9][10]. - Market-Perform ratings are assigned to AAL, ANTO, BHP, and others, with adjustments made to price targets reflecting recent production results and exchange rate changes [10][12][13]. Conclusion - The mining industry is entering a potentially robust period for M&A activity, driven by favorable credit conditions and high EBITDA margins. Companies are likely to focus on acquiring existing assets to bolster production, particularly in the copper sector, amidst concerns of future supply deficits [1][3][5].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | 第 1 頁 共 ...